526191-19-5

Upstream product

• 39742-60-4 1-(2-phenylethyl)-4-piperidinone 
• 103-63-9 1-phenyl-2-bromoethane 
• 41979-39-9 4-piperidone hydrochloride 
• 122-78-1 phenylacetaldehyde 
• 125541-22-2 1-(tert-butoxycarbonyl)-4-phenylaminopiperidine 
• 1501-26-4 methyl 4-(chlorocarbonyl)butyrate 
• 21409-26-7 (1-Phenethyl-piperidin-4-yl)-phenyl-amine 
• 108-55-4 glutaric anhydride, 

Downstream Products

• 1338727-35-7 C₂₄H₂₉N₂O₂⁽¹⁺⁾*ClHO₄*ClO₄^(1-) 
• 1338727-48-2 tryptophan 3,5-bis(trifluoromethyl)benzyl ester 5-oxo-5-((1-phenethylpiperidin-4-yl)(phenyl)amino)pentanoate 
• 1379800-16-4 N₁-[2-(cyclohexylamino)-2-oxo-1-phenylethyl]-N₁,N₅-diphenyl-N₅-[1-(2-phenylethyl)piperidin-4-yl]pentanediamide 
• 1379800-14-2 N₁-(4-bromophenyl)-N₁-[2-(cyclohexylamino)-2-oxo-1-phenylethyl]-N₅-phenyl-N₅-[1-(2-phenylethyl)piperidin-4-yl]pentanediamide 

Relevant academic research and scientific papers

Combatting Synthetic Designer Opioids: A Conjugate Vaccine Ablates Lethal Doses of Fentanyl Class Drugs

Fentanyl is an addictive prescription opioid that is over 80 times more potent than morphine. The synthetic nature of fentanyl has enabled the creation of dangerous "designer drug" analogues that escape toxicology screening, yet display comparable potency to the parent drug. Alarmingly, a large number of fatalities have been linked to overdose of fentanyl derivatives. Herein, we report an effective immunotherapy for reducing the psychoactive effects of fentanyl class drugs. A single conjugate vaccine was created that elicited high levels of antibodies with cross-reactivity for a wide panel of fentanyl analogues. Moreover, vaccinated mice gained significant protection from lethal fentanyl doses. Lastly, a surface plasmon resonance (SPR)-based technique was established enabling drug-specificity profiling of antibodies derived directly from serum. Our newly developed fentanyl vaccine and analytical methods may assist in the battle against synthetic opioid abuse.

ADJUVANTED CONJUGATE OPIOID VACCINE

The adjuvanted conjugate opioid vaccine described herein is a conjugate of a protein carrier and at least one opioid backbone component or hapten conjugated thereto, admixed with at least one adjuvant. Anti-opioid effects are demonstrated after administration of a vaccine made up of the CRM197 protein carrier linked to a FEN backbone, combined with adjuvants such as dmLT or LTA1.

OPIOID HAPTENS, CONJUGATES, VACCINES, AND METHODS OF GENERATING ANTIBODIES

The disclosure provides, inter alia, opioid haptens, opioid hapten conjugates, opioid vaccines, methods of treating or preventing opioid use disorder, methods of treating opioid overdose, and methods of generating and/or isolating antibodies selective for opioids.

A chemically contiguous hapten approach for a heroin-fentanyl vaccine

Background: Increased death due to the opioid epidemic in the United States has necessitated the development of new strategies to treat addiction. Monoclonal antibodies and antidrug vaccines provide a tool that both aids addiction management and reduces the potential for overdose. Dual drug vaccines formulated by successive conjugation or by mixture have certain drawbacks. The current study examines an approach for combatting the dangers of fentanyl-laced heroin, by using a hapten with one epitope that has domains for both fentanyl and heroin. Results: We evaluated a series of nine vaccines developed from chemically contiguous haptens composed of both heroin- and fentanyl-like domains. Analysis of the results obtained by SPR and ELISA revealed trends in antibody affinity and titers for heroin and fentanyl based on epitope size and linker location. In antinociception studies, the best performing vaccines offered comparable protection against heroin as our benchmark heroin vaccine, but exhibited attenuated protection against fentanyl compared to our fentanyl vaccine. Conclusion: After thorough investigation of this strategy, we have identified key considerations for the development of a chemically contiguous heroin-fentanyl vaccine. Importantly, this is the first report of such a strategy in the opioid-drug-vaccine field.

Synthesis and Investigation of Mixed μ-Opioid and δ-Opioid Agonists as Possible Bivalent Ligands for Treatment of Pain

Several studies have suggested functional association between μ-opioid and δ-opioid receptors and showed that μ-activity could be modulated by δ-ligands. The general conclusion is that agonists for the δ-receptor can enhance the analgesic potency and effi

SYNTHETIC OPIOID VACCINE

Fentanyl is an addictive prescription opioid that is over 80 times mora potent than morphine. The synthetic nature of fentanyl has enabled the creation of dangerous "designer drug' analogues that escape toxicology screening, yet display comparable potency to the parent drug. Alarmingly, a large number of fatalities have been linked to overdose of fentanyl derivatives. Herein, we report an effective immunotherapy for reducing the psychoactive effects of fentanyl class drugs. A single conjugate vaccine was created that elicited high levels of antibodies with cross-reactivity for a wide panel of fentanyl analogues, Moreover, vaccinated mice gained significant protection from lethal fentanyl doses. Lastly, a surface plasmon resonance (SPR)-based technique was established enabling drug specificity profiling of antibodies derived directly from serum. Our newiy developed fentanyl vaccine and analytical methods may assist in the battle against synthetic opioid abuse.

Designing and synthesis of novel amidated fentanyl analogs

Some new amidated fentanyl (=N-[1-(2-phenylethyl)piperidin-4-yl]-N- phenylpropanamide) analogs with a 4-(N-phenylamido)piperidine scaffold and additional amide bonds have been designed and synthesized through Ugi four-component reaction (Ugi-4CR). Good-to-high yields, diversity-oriented synthesis, and possible applications in drug discovery are advantages of this approach. Copyright

Synthesis and biological evaluation of new opioid agonist and neurokinin-1 antagonist bivalent ligands

Newly designed bivalent ligands - opioid agonist/NK1-antagonists have been synthesized. The synthesis of new starting materials - carboxy-derivatives of Fentanyl (1a-1c) was developed. These products have been transformed to 'isoimidium perchlorates' (2a-